Baird Initiates Coverage on Regeneron (REGN) with a Neutral
More News related to REGN
- Sanofi-aventis (SNY) and Regeneron (REGN) Announce Results from Phase 2 Study with Aflibercept (VEGF Trap) in Advanced Ovarian Cancer Patients
- Sanofi-aventis and Regeneron Announce Results from Phase 2 Study with Aflibercept (VEGF Trap) in Advanced Ovarian Cancer Patients with Recurrent Symptomatic Malignant Ascites
- Regeneron Converts Interleukin-1 Antibody Opt-In Rights to Royalty Agreement
- Regeneron Announces Presentation at the 8th Annual Needham Life Sciences Conference
- Barclays Gets Bullish On US Biotechnology Sector (BBH)
Baird initiates coverage on Regeneron (Nasdaq: REGN) with a Neutral rating.
Regeneron Pharmaceuticals, Inc. (Regeneron) is a biopharmaceutical company that discovers, develops, and intends to commercialize pharmaceutical products for the treatment of serious medical conditions.
Related Categories
New CoverageStocks Mentioned
-1.09Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
